# Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

> **NCT01053728** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 46 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** SAR161271
- **DRUG:** Insulin glargine HOE901

## Key facts

- **NCT ID:** NCT01053728
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2011-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01053728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01053728, "Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01053728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*